The UK government has initiated formal consultations with the European Union, with the aim of finalizing UK participation in EU science and research programs. This follows persistent delays by the EU in implementing the agreement reached under the Trade and Cooperation Agreement (TCA).
The UK Foreign Office wrote to the European Commission on August 16, 2022, to request consultations on finalizing the UK’s participation in EU Programs (Horizon Europe, Copernicus, Euratom Research and Training, Fusion for Energy) and access to program services (Space Surveillance and Tracking) as soon as possible.
Through the Brexit deal struck between the UK and European Union, the UK would be part of Horizon Europe. However, small UK pharma and biotech companies have since expressed concerns that they are being excluded.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze